Statera Biopharma Stock Book Value Per Share
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
Statera Biopharma fundamentals help investors to digest information that contributes to Statera Biopharma's financial success or failures. It also enables traders to predict the movement of Statera Pink Sheet. The fundamental analysis module provides a way to measure Statera Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Statera Biopharma pink sheet.
Statera |
Statera Biopharma Company Book Value Per Share Analysis
Statera Biopharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Statera Biopharma Book Value Per Share | (0.20) X |
Most of Statera Biopharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Statera Biopharma is about -0.202 times. This is 88.12% lower than that of the Healthcare sector and 99.92% lower than that of the Biotechnology industry. The book value per share for all United States stocks is 100.01% higher than that of the company.
Statera Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.Statera Biopharma is currently under evaluation in book value per share category among its peers.
Statera Fundamentals
| Return On Equity | -2.87 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (5.73) % | ||||
| Current Valuation | 12.92 M | ||||
| Shares Outstanding | 54.66 M | ||||
| Shares Owned By Insiders | 15.93 % | ||||
| Shares Owned By Institutions | 5.41 % | ||||
| Number Of Shares Shorted | 1.25 M | ||||
| Price To Book | 0.16 X | ||||
| Price To Sales | 1.61 X | ||||
| Revenue | 1.49 M | ||||
| Gross Profit | 998.72 K | ||||
| EBITDA | (97.27 M) | ||||
| Net Income | (101.88 M) | ||||
| Cash And Equivalents | 506.1 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 10.62 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.20) X | ||||
| Cash Flow From Operations | (28.19 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.76) X | ||||
| Number Of Employees | 46 | ||||
| Market Capitalization | 1.97 M | ||||
| Total Asset | 21.17 M | ||||
| Z Score | -13.2 | ||||
| Net Asset | 21.17 M |
About Statera Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Statera Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Statera Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Statera Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |